Medpace reports second-quarter 2026 revenue of $707.3 million, raises full-year outlook details
The clinical research organization posted 17.2% revenue growth and $795.7 million in net new business awards, while narrowing its 2026 revenue guidance range.
Medpace Holdings reported financial results for the second quarter ended June 30, 2026, in a release dated July 22, 2026. Revenue reached $707.3 million in the quarter, up 17.2% from $603.3 million a year earlier, with a backlog conversion rate of 24.1%.1
Net new business awards totaled $795.7 million, a 28.2% increase from $620.5 million in the prior-year period, producing a net book-to-bill ratio of 1.13x.1 Backlog as of June 30, 2026 stood at $3,014.2 million, up 4.9% from $2,873.6 million a year earlier.1
Second-quarter GAAP net income was $121.4 million, or $4.25 per diluted share, compared with $90.3 million, or $3.10 per diluted share, in the same period of 2025, with net income margin rising to 17.2% from 15.0%.1
For the balance sheet, the company held $502.7 million in cash and cash equivalents at June 30, 2026, and generated $162.0 million in operating cash flow during the quarter.1 Medpace repurchased 705,616 shares for $294.7 million in the quarter and had $527.0 million remaining under its share repurchase authorization as of June 30, 2026.1
On guidance, the company forecasts full-year 2026 revenue between $2.805 billion and $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion.1 Full-year GAAP net income is expected between $494.0 million and $514.0 million, with EBITDA forecast at $618.0 million to $642.0 million.1 The guidance does not account for any share repurchases made after June 30, 2026.1
Medpace will hold a conference call at 9:00 a.m. ET on Thursday, July 23, 2026, to discuss the results.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.